REGN
Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The profitability sub-score of 17.6/20 is a significant positive contributor, reflecting strong filing-derived net margins, operating margins, and return on assets that anchor the overall 57.5 score.
- The dividend sub-score of 20.0/20 adds the maximum possible points to the composite, reflecting exceptional free cash flow payout coverage and dividend consistency as recorded in the 10-K filing.
- Despite weak growth and momentum scores, the combination of high profitability and maximum dividend marks produces a composite score in the mid-range, placing Regeneron above speculative-only biotechs but below high-growth or financially pristine research candidates.
Why Not Higher
- The theme sub-score of 0.0/20 represents a substantial gap in the model's scoring framework, as Regeneron's business does not align with any of the macro themes tracked, costing the composite score up to 20 full points that better-positioned companies capture.
- The combined effect of a growth sub-score of 10.0/20, momentum sub-score of 7.4/20, and financial health sub-score of 10.0/20 means three of the six scoring dimensions are performing at or below the midpoint, preventing the score from reaching the higher tiers of the model.
Data Confidence
9 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Regeneron Pharmaceuticals, Inc. is a U.S.-based biotechnology company known for developing and commercializing medicines for serious diseases, with its flagship product Dupixent (dupilumab) treating atopic dermatitis, asthma, and other inflammatory conditions, alongside EYLEA for retinal diseases and a growing oncology and rare disease pipeline. The company's overall model score of 57.5/100 reflects a mixed picture: strong profitability metrics drive a sub-score of 17.6/20, reflecting robust net and operating margins along with solid return on assets derived from its commercial portfolio, while the financial health sub-score of 10.0/20 suggests moderate leverage or interest coverage constraints that temper the overall assessment. The growth sub-score of 10.0/20 indicates that year-over-year revenue, net income, or EPS growth rates are not accelerating strongly enough to push the score higher, possibly reflecting competitive pressure on EYLEA from biosimilar entrants and the increasing revenue dependence on Dupixent's continued expansion. The dividend sub-score of 20.0/20 is notable and somewhat unusual for a biotechnology firm, suggesting strong free cash flow coverage and consistent dividend-per-share metrics as captured in the filing data, which is why the model's best-scoring profile for Regeneron is dividend income at 71.3 rather than a growth or speculative label. However, the theme sub-score of 0.0/20 reflects that the model did not identify macro thematic exposures — such as AI, energy transition, or emerging-market infrastructure — pulling the composite score down meaningfully. The core research tradeoff for Regeneron is therefore between its demonstrable commercial profitability and cash generation on one hand, and slowing growth dynamics, balance sheet constraints, and an absence of macro-theme tailwinds on the other.
Plain English
Regeneron is a large American biotech company that makes medicines for conditions like eczema, eye diseases, and cancer — its biggest product is Dupixent, which millions of patients use. A model score of 57.5 out of 100 means the research model sees real strengths, especially in how profitably the company runs and how well it generates cash, but also real weaknesses in growth momentum and financial structure that prevent a higher rating. The High risk rating reflects the fact that biotech companies like Regeneron depend heavily on a small number of key products, face patent cliffs and biosimilar competition, and operate in a heavily regulated environment where clinical or regulatory setbacks can have outsized consequences. Researchers would treat this as a company worth examining more closely rather than dismissing, particularly given its dividend-income profile score.
Bull Case vs. Bear Case
Bull Case
- The profitability sub-score of 17.6/20 indicates that Regeneron operates with strong net and operating margins and solid return on assets, suggesting its commercial products generate durable earnings from SEC filing data.
- The dividend sub-score of 20.0/20 — the maximum — reflects exceptional free cash flow coverage of dividends and strong dividend-per-share metrics, which is rare for a biotechnology company and signals financial discipline.
- The model's best-scoring profile is dividend income at 71.3, indicating that for researchers focused on cash return and income generation, Regeneron's filing-derived fundamentals are particularly well-aligned.
Bear Case
- The growth sub-score of 10.0/20 is mediocre, suggesting that year-over-year revenue, net income, and EPS growth rates captured in the FY2025 10-K filing are not materially accelerating, which may reflect EYLEA biosimilar pressure eroding a historically significant revenue stream.
- The financial health sub-score of 10.0/20 suggests that leverage ratios or interest coverage metrics from the balance sheet are only moderate, limiting the company's financial flexibility relative to peers with cleaner balance sheets.
- The momentum sub-score of 7.4/20 is the weakest operational sub-score, indicating that quarter-over-quarter improvements in revenue, earnings, or margins within the filing period are limited, pointing to near-term operational headwinds.
What Could Change the Picture
Bullish Triggers
- A material acceleration in revenue and EPS growth in a subsequent 10-K filing — driven by new Dupixent label expansions, oncology pipeline approvals, or strong uptake of new pipeline assets — would likely improve the growth sub-score from 10.0 and lift the composite meaningfully.
- Improvement in the financial health sub-score through debt reduction, stronger interest coverage ratios, or a cleaner leverage profile as reflected in future balance sheet filings would address one of the current drag factors on the overall model score.
Bearish Triggers
- A deterioration in the dividend sub-score — for example, if free cash flow coverage of dividends declined significantly in a future filing due to increased R&D spend, litigation costs, or product revenue erosion — would remove the primary pillar supporting the current 57.5 score.
- Further weakening of the momentum sub-score in a subsequent quarterly or annual filing, particularly if operating margins compress due to biosimilar competition against EYLEA or pricing pressure on Dupixent, would signal a worsening fundamental trajectory and reduce the research attractiveness of this candidate.
Red Flags
- The momentum sub-score of 7.4/20 combined with a growth sub-score of 10.0/20 together suggest that both the trajectory and the rate of top- and bottom-line expansion are simultaneously weak, which for a company in a competitive therapeutic market warrants close monitoring in subsequent filings.
- The theme sub-score of 0.0/20 indicates the model identified no macro-thematic tailwinds for Regeneron, meaning the company's near-term revenue outlook is almost entirely dependent on existing commercial products rather than structural growth themes.
Risk Profile
High RiskThe High risk rating for Regeneron reflects the company's concentration in a handful of commercial products — particularly Dupixent and EYLEA — where patent expirations, biosimilar competition, and regulatory or clinical trial failures can rapidly alter the earnings profile captured in future filings. As a biotechnology firm, Regeneron also operates in a capital-intensive, heavily regulated environment where pipeline setbacks or changes in drug pricing policy can have outsized impacts on the financial metrics the model relies upon.
Key Catalysts to Watch
The most critical variables to monitor for Regeneron are the trajectory of Dupixent revenues and label expansions into new indications, as well as EYLEA's ability to retain market share against biosimilar competition, both of which will directly drive future growth and momentum sub-scores. Regulatory decisions on pipeline oncology and rare disease assets, along with any significant changes to free cash flow generation that could affect the currently perfect dividend sub-score, are the key filing-derived signals researchers should track.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.